Corbus Pharmaceuticals Holdings, Inc. posts 2026 first quarter financial results and corporate update

Corbus Pharmaceuticals Holdings, Inc. posts 2026 first quarter financial results and corporate update
Corbus posts Q1 2026 results

Corbus Pharmaceuticals Holdings, Inc. released its corporate update and financial results for the first quarter ended March 31, 2026.

The announcement provides investors and stakeholders with insights into recent business developments and the company’s financial performance during the opening quarter of the year. Further details are available via the official company report.

Earlier this year, Corbus Pharmaceuticals hit a milestone in its CRB-913 obesity trial by initiating the last patient first visit in the 240-participant CANYON-1 study, which is set for completion in summer 2026 (full story). The company also announced plans to present updated Phase 1/2 results for CRB-701 at the 2026 ASCO annual meeting (more details). Both developments come as Corbus continues to advance its pipeline through the year.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.